Brainstorm Cell Therapeutics Profit Margin

Brainstorm Cell Therapeutics (BCLI) currently reports a profit margin of 1628.38% as of June 2026. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore Brainstorm Cell Therapeutics's profit margin history and peer comparisons.

Brainstorm Cell Therapeutics's profit margin of 1628.38% is higher than the Healthcare sector average of 13.89%. That is roughly 11627.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Brainstorm Cell Therapeutics's current 1628.38% should be judged against Healthcare norms (sector average: 13.89%) and against BCLI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 1628.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Brainstorm Cell Therapeutics, and consider following BCLI for alerts when major investors trade the stock.

Brainstorm Cell Therapeutics is classified in the Healthcare sector. On profit margin, it currently shows 1628.38% versus a sector average near 13.89%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCLI with unrelated industries.